Drupal.behaviors.print = function(context) {window.print();window.close();}>
MDx/CDx Focus: Myriad's Prolaris Initially Denied by Noridian; Life Tech's Pervenio Lung Cancer Dx
September 26, 2012
MDx/CDx Focus: Myriad's Prolaris Initially Denied by Noridian; Life Tech's Pervenio Lung Cancer Dx
Full-text access for premium subscribers only.
Existing premium subscribers
login here
.
New to GenomeWeb?
Register here
quickly.
Related Stories
Myriad Plans NGS-Based Tests, Says Whole-Genome Sequencing Not Yet Ready for Clinical Use
January 4, 2012 / Clinical Sequencing News
Myriad to Replace BRACAnalysis, Other Hereditary Cancer Tests with MyRisk Panel
May 9, 2013 / GenomeWeb Daily News
Myriad Partners with RainDance for Front End of NGS-based Hereditary Cancer Panel Test
April 17, 2013 / Clinical Sequencing News
Asuragen Launches Cancer Panels Optimized for FFPE Tissue; Plans to Sell Proprietary Reagents
April 10, 2013 / Clinical Sequencing News
Life Tech's AmpliSeq BRCA 1/2 Panel Launch Puts Pressure on Long-Term Myriad Monopoly
April 3, 2013 / Pharmacogenomics Reporter